| 10.62 -0.14 (-1.3%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.87  |
1-year : | 18.09 |
| Resists | First : | 12.73 |
Second : | 15.48 |
| Pivot price | 10.29 |
|||
| Supports | First : | 8.28 | Second : | 6.89 |
| MAs | MA(5) : | 10.72 |
MA(20) : | 10.75 |
| MA(100) : | 10.01  |
MA(250) : | 8.37 |
|
| MACD | MACD : | -0.8 |
Signal : | -1 |
| %K %D | K(14,3) : | 56.7 |
D(3) : | 52.1 |
| RSI | RSI(14): 44.2 |
|||
| 52-week | High : | 20 | Low : | 4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NYXH ] has closed below upper band by 39.4%. Bollinger Bands are 33.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.01 - 11.07 | 11.07 - 11.13 |
| Low: | 9.63 - 9.69 | 9.69 - 9.75 |
| Close: | 10.52 - 10.63 | 10.63 - 10.73 |
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Mon, 15 Apr 2024
Nyxoah SA Welcomes New Chief Medical Officer - TipRanks.com - TipRanks
Thu, 07 Mar 2024
Nyxoah S.A. (NASDAQ:NYXH) Q4 2023 Earnings Call Transcript - Yahoo Finance
Wed, 06 Mar 2024
Oppenheimer raises Nyxoah SA stock target to $17 on strong revenue - Investing.com
Tue, 05 Mar 2024
Stifel Maintains Buy Rating for Nyxoah: Here's What You Need To Know - Markets Insider
Tue, 05 Mar 2024
Nyxoah S.A. (NYXH) Q4 2023 Earnings Call Transcript - Seeking Alpha
Tue, 05 Mar 2024
Nyxoah SA (NYXH) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 29 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 45.1 (%) |
| Held by Institutions | 23.8 (%) |
| Shares Short | 258 (K) |
| Shares Short P.Month | 176 (K) |
| EPS | -1.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.42 |
| Profit Margin | 0 % |
| Operating Margin | -594.2 % |
| Return on Assets (ttm) | -20.9 % |
| Return on Equity (ttm) | -39.6 % |
| Qtrly Rev. Growth | 39.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.15 |
| EBITDA (p.s.) | -1.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -6.44 |
| PEG Ratio | 0 |
| Price to Book value | 3.1 |
| Price to Sales | 70.01 |
| Price to Cash Flow | -6.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|